Economic impact of chronic prostatitis

Anna M S Duloy, Elizabeth Calhoun, J. Quentin Clemens

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

There are four types of prostatitis, including type I (acute bacterial prostatitis), type II (chronic bacterial prostatitis), type 111 (chronic prostatitis/chronic pelvic pain syndrome, or CP/CPPS), and type IV (asymptomatic inflammatory prostatitis). These prostatitis conditions account for approximately 2 million office visits each year to primary care physicians and urologists. The annual cost to treat prostatitis is approximately $84 million. Compared with control subjects, men with prostatitis incur significantly greater costs, predominantly due to increased outpatient visits and pharmacy expenses. CP/CPPS is the most common type of prostatitis. The condition is characterized by chronic, idiopathic pelviperineal pain. Due to the lack of effective treatments for CP/CPPS, the per-person costs associated with the condition are substantial and are similar to those reported for peripheral neuropathy, low back pain, fibromyalgia, and rheumatoid arthritis. Costs appear to be higher in men with more severe symptoms. Indirect costs (eg, work and productivity loss) are incurred by many patients with CP/CPPS. Identification of effective treatments for CP/CPPS would be expected to substantially reduce the costs associated with the condition.

Original languageEnglish (US)
Pages (from-to)336-339
Number of pages4
JournalCurrent Urology Reports
Volume8
Issue number4
DOIs
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

Prostatitis
Economics
Costs and Cost Analysis
Office Visits
Pelvic Pain
Fibromyalgia
Primary Care Physicians
Peripheral Nervous System Diseases
Low Back Pain
Chronic Pain
Rheumatoid Arthritis
Outpatients
Pain

ASJC Scopus subject areas

  • Urology

Cite this

Economic impact of chronic prostatitis. / Duloy, Anna M S; Calhoun, Elizabeth; Clemens, J. Quentin.

In: Current Urology Reports, Vol. 8, No. 4, 07.2007, p. 336-339.

Research output: Contribution to journalArticle

Duloy, Anna M S ; Calhoun, Elizabeth ; Clemens, J. Quentin. / Economic impact of chronic prostatitis. In: Current Urology Reports. 2007 ; Vol. 8, No. 4. pp. 336-339.
@article{69399e9fade2431a95bacecc40c85b8e,
title = "Economic impact of chronic prostatitis",
abstract = "There are four types of prostatitis, including type I (acute bacterial prostatitis), type II (chronic bacterial prostatitis), type 111 (chronic prostatitis/chronic pelvic pain syndrome, or CP/CPPS), and type IV (asymptomatic inflammatory prostatitis). These prostatitis conditions account for approximately 2 million office visits each year to primary care physicians and urologists. The annual cost to treat prostatitis is approximately $84 million. Compared with control subjects, men with prostatitis incur significantly greater costs, predominantly due to increased outpatient visits and pharmacy expenses. CP/CPPS is the most common type of prostatitis. The condition is characterized by chronic, idiopathic pelviperineal pain. Due to the lack of effective treatments for CP/CPPS, the per-person costs associated with the condition are substantial and are similar to those reported for peripheral neuropathy, low back pain, fibromyalgia, and rheumatoid arthritis. Costs appear to be higher in men with more severe symptoms. Indirect costs (eg, work and productivity loss) are incurred by many patients with CP/CPPS. Identification of effective treatments for CP/CPPS would be expected to substantially reduce the costs associated with the condition.",
author = "Duloy, {Anna M S} and Elizabeth Calhoun and Clemens, {J. Quentin}",
year = "2007",
month = "7",
doi = "10.1007/s11934-007-0081-x",
language = "English (US)",
volume = "8",
pages = "336--339",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Economic impact of chronic prostatitis

AU - Duloy, Anna M S

AU - Calhoun, Elizabeth

AU - Clemens, J. Quentin

PY - 2007/7

Y1 - 2007/7

N2 - There are four types of prostatitis, including type I (acute bacterial prostatitis), type II (chronic bacterial prostatitis), type 111 (chronic prostatitis/chronic pelvic pain syndrome, or CP/CPPS), and type IV (asymptomatic inflammatory prostatitis). These prostatitis conditions account for approximately 2 million office visits each year to primary care physicians and urologists. The annual cost to treat prostatitis is approximately $84 million. Compared with control subjects, men with prostatitis incur significantly greater costs, predominantly due to increased outpatient visits and pharmacy expenses. CP/CPPS is the most common type of prostatitis. The condition is characterized by chronic, idiopathic pelviperineal pain. Due to the lack of effective treatments for CP/CPPS, the per-person costs associated with the condition are substantial and are similar to those reported for peripheral neuropathy, low back pain, fibromyalgia, and rheumatoid arthritis. Costs appear to be higher in men with more severe symptoms. Indirect costs (eg, work and productivity loss) are incurred by many patients with CP/CPPS. Identification of effective treatments for CP/CPPS would be expected to substantially reduce the costs associated with the condition.

AB - There are four types of prostatitis, including type I (acute bacterial prostatitis), type II (chronic bacterial prostatitis), type 111 (chronic prostatitis/chronic pelvic pain syndrome, or CP/CPPS), and type IV (asymptomatic inflammatory prostatitis). These prostatitis conditions account for approximately 2 million office visits each year to primary care physicians and urologists. The annual cost to treat prostatitis is approximately $84 million. Compared with control subjects, men with prostatitis incur significantly greater costs, predominantly due to increased outpatient visits and pharmacy expenses. CP/CPPS is the most common type of prostatitis. The condition is characterized by chronic, idiopathic pelviperineal pain. Due to the lack of effective treatments for CP/CPPS, the per-person costs associated with the condition are substantial and are similar to those reported for peripheral neuropathy, low back pain, fibromyalgia, and rheumatoid arthritis. Costs appear to be higher in men with more severe symptoms. Indirect costs (eg, work and productivity loss) are incurred by many patients with CP/CPPS. Identification of effective treatments for CP/CPPS would be expected to substantially reduce the costs associated with the condition.

UR - http://www.scopus.com/inward/record.url?scp=34547401595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547401595&partnerID=8YFLogxK

U2 - 10.1007/s11934-007-0081-x

DO - 10.1007/s11934-007-0081-x

M3 - Article

C2 - 18519019

AN - SCOPUS:34547401595

VL - 8

SP - 336

EP - 339

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 4

ER -